FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer’s Disease: Benefits and Pitfalls

In June 2021, the US Federal Drug and Food Administration (FDA) granted accelerated approval for the antibody aducanumab and, in January 2023, also for the antibody lecanemab, based on a perceived drug-induced removal of cerebral amyloid-beta as assessed by amyloid-PET and, in the case of lecanemab,...

Descripción completa

Detalles Bibliográficos
Autores principales: Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Costa, Tommaso, Kepp, Kasper P., Castellani, Rudolph J., Perry, George, Alavi, Abass, Barrio, Jorge R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341276/
https://www.ncbi.nlm.nih.gov/pubmed/37443645
http://dx.doi.org/10.3390/diagnostics13132254

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341276/
https://www.ncbi.nlm.nih.gov/pubmed/37443645
http://dx.doi.org/10.3390/diagnostics13132254

Ejemplares similares